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To investigate the molecular basis of muscle disease and gnathodiaphyseal dysplasia (GDD) in
a large kindred with 11 (6 women and 5 men) affected family members.
Methods
We performed clinical assessment of 3 patients and collected detailed clinical and family history
data on 8 additional patients. We conducted molecular genetic analyses on 5 patients using
comprehensive neuromuscular disorder panels, exome sequencing (ES), and targeted testing
for specific genetic variants. We analyzed the segregation of the muscle and bone phenotypes
with the underlying molecular cause.
Results
The unique clinical presentation of recurrent episodes of rhabdomyolysis associated with
muscle cramps, hyperCKemia, muscle hypertrophy, with absent or mild muscle weakness, as
well as cemento-osseous lesions of the mandible, with or without bone fractures and other
skeletal abnormalities, prompted us to look for the underlying molecular cause of the disorder
in this kindred. Molecular testing revealed a missense variant in anoctamin 5 (ANO5) desig-
nated as c.1538C>T; p.Thr513Ile, which was previously described in a large kindred with GDD.
In silico analysis, searching publicly available databases, segregation analysis, as well as func-
tional studies performed by another group provide strong evidence for pathogenicity of the
variant. ES data in the proband excluded the contribution of additional genetic factors.
Conclusions
This report described the coexistence of muscle and bone phenotypes in the same patients with
ANO5-related disorder. Our data challenge recent results that suggested complete dichotomy
of these phenotypes and the proposed loss-of-function and gain-of-function mechanisms for
the skeletal and muscle phenotypes, respectively.
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Anoctamin 5 (ANO5; MIM# 608662) belongs to the trans-
membrane 16 (TMEM16) protein family. The gene has 22 exons
and encodes a 913–amino acid protein and is not only abun-
dantly expressed in skeletal and cardiac muscles but also found in
growth plate chondrocytes and in osteoblasts, illustrating its im-
portant role in muscle and bone development and function.
Pathogenic ANO5 variants cause 2 distinct disorders with no
overlapping features. Heterozygous variants are associated with
autosomal dominant (AD) gnathodiaphyseal dysplasia (GDD;
MIM# 166260), characterized by cemento-osseous lesions of the
mandible and maxilla, bowing/sclerosis of tubular bones, and
generalized bone fragility with recurrent fractures.1 Biallelic variants
cause 2 autosomal recessive (AR) myopathies: Miyoshi muscular
dystrophy-3 (MMD3; MIM# 613319) and limb-girdle muscular
dystrophy-12 (LGMDR12; MIM# 611307). The spectrum of
clinical findings in the AR disease ranges from asymptomatic
hyperCKemia, exercise-induced myalgia, and predominantly late-
onset proximal muscle weakness (LGMDR12) to early-onset calf
distal myopathy (MMD3).2 Herein, we report a large kindredwith
multiple family members presenting with muscle and skeletal
findings that segregated with a missense ANO5 variant, which was
previously described in a large kindred with GDD.
Methods
Standard Protocol Approvals, Registrations,
and Patient Consents
Written informed consent and authorization for publication
were obtained from patients II-2, III-1, III-4, III-10, and IV-6.
The Washington University in St. Louis Media Authorization
for the Use and Disclosure of Protected Health Information
form was used for all patients.
Genetic Testing
Molecular genetic analyses were performed on 5 patients and
included comprehensive neuromuscular disorder panels,
exome sequencing (ES), and targeted testing for specific ge-
netic variants, as detailed in the Supplementary Material
(links.lww.com/NXG/A439).
Data Availability




The proband (III-1) (Figure 1) is a 46-year-old White man
who presented with episodes of rhabdomyolysis with severe
painful muscle cramps since age 6 years. The cramps involved
legs, arms, and abdominal muscles; occurred 3–5 times a year;
lasted for 5–7 days; disrupted his daily life activities; and were
associated with hyperCKemia with the highest creatine kinase
(CK) value at 8,000 IU/L (normal 207–250). Between epi-
sodes, he complained of generalized fatigue and muscle
weakness. He also had several bone fractures between ages 7
and 17 years, including 8 fractures in his left forearm and 1
fracture in left femur. On physical examination, he had gen-
eralized muscle hypertrophy and maintained normal strength
in all muscles. His workup included a normal EMG and a
muscle biopsy, which revealed mild, nonspecific myopathic
changes (Figure 2). His skeletal survey showed generalized
diaphyseal thickening of long bones (Figure 3).
Patient III-10 (Figure 1), maternal cousin of the proband, is a
42-year-old woman who presented with episodes of rhabdo-
myolysis with exertional painful muscle cramps and weakness
associated with hyperCKemia with highest CK value at 6,000
IU/L. Her symptoms began in her late 20s and were limited to
her calves. Throughout the years, her symptoms progressed to
diffuse muscle pains, which limited her activity. Over the past
4 years, she started complaining of increased shortness of
breath and fatigue. At age 36 years, she had compartment
syndrome requiring emergent fasciotomy. She had 3 fractures
in her arm and leg between ages 5 and 9 years and had
multiple cemento-ossifying fibromas (COFs) in her mandi-
ble. Neurologic examination showed muscle hypertrophy in
the biceps, forearms, and calves bilaterally; muscle weakness
4+/5 on hip flexion bilaterally; and full strength throughout all
other muscles. Reflexes were diffusely reduced. Muscle biopsy
showed atrophy of mostly type IIB fibers suggesting disuse
and internal nuclei in occasional fibers. EMG and nerve
conduction studies were normal.
The son of patient III-10, IV-6 (Figure 1) is 20 years old who
also presented with rhabdomyolysis with exertional painful
muscle cramps, muscle hypertrophy, and hyperCKemia. His
muscle symptoms began at age 16 years with severe diffuse
muscle stiffness and pain, both exacerbated by physical ac-
tivity. CK levels at baseline were elevated at the 10-fold nor-
mal range; however, there have been several episodes of
rhabdomyolysis with CK values in the 25,000 IU/L range; 4 of
these episodes at age 18–19 years were complicated by the
compartment syndrome involving all 4 extremities requiring
multiple fasciotomies. One of these episodes led to left pe-
roneal nerve injury. He also had multiple mandibular COFs
first detected at 9 years of age and required debulking and
extraction of many of his lower teeth at 9 and 12 years of age.
Glossory
AD = autosomal dominant; ANO5 = anoctamin 5; AR = autosomal recessive; CK = creatine kinase; COF = cemento-ossifying
fibromas; ES = exome sequencing; GDD = gnathodiaphyseal dysplasia; LGMDR12 = limb-girdle muscular dystrophy-12;
MD = muscle disease; MMD3 = Miyoshi muscular dystrophy-3; TMEM16 = transmembrane 16.
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He also had fractures in his clavicle and spine at age 14 and 16
years, respectively. Neurologic examination showed diffuse
muscle hypertrophy, predominantly in the calves and fore-
arms. There were 4/5 hip flexion bilaterally and 2/5 left ankle
dorsiflexion and eversion weakness. Deep tendon reflexes
were diffusely absent. Muscle biopsy showed occasional
muscle fibers with internal nuclei, but otherwise nonspecific.
EMG revealed mild myopathic motor units in the deltoid,
otherwise normal.
The family history (Figure 1) was significant for 5 additional
affected female patients, all had COFs and 3 had recurrent
muscle cramps, and for 3 affected male patients with recurrent
episodes of muscle cramps and COFs, as detailed in the
Supplementary Material (links.lww.com/NXG/A439).
Molecular Results
Molecular testing of patients II-2, III-1, III-4, III-10, and IV-6
revealed the ANO5 (NM_213599.2) variant p.Thr513Ile
(ACC>ATC): c.1538C>T. The proband also had the variant
c.4604G>A; p.Arg1535His in COL6A3 (NM_004369.4),
which was not detected in all family members who underwent
molecular testing. ES for the proband confirmed the maternal
inheritance of the ANO5 variant, but no other variants were
identified.
Discussion
We reported a large kindred with multiple family members
presenting with an AD disorder featuring recurrent episodes
of muscle cramps, generalized muscle weakness, muscle hy-
pertrophy, hyperCKemia, and bone findings consistent with
GDD. The 2 phenotypes largely segregated with the
p.Thr513Ile ANO5 variant. This report documented the co-
existence of the muscle and bone phenotypes in patients
heterozygous for pathogenic ANO5 variants. One previous
study reported the presence of “facial dysplasia with a
prominent jaw” in a patient with AR ANO5-related disorder,
but no convincing data were provided to support the presence
of GDD.3 The absence of the COL6A3 variant in other family
members and negative ES in the proband highly support that
Figure 2 Muscle Pathology Findings in a Patient With AD ANO5-Related Disorder
Muscle biopsy findings in the proband (III-1). H&E
(A) and Gomori trichrome (B) stains (magnified at
100×) showing mild variation of fiber size and in-
creased internal nuclei; both are nonspecific
myopathic findings. AD = autosomal dominant;
ANO5 = anoctamin 5.
Figure 1 Pedigree of a Large Family With ANO5-Related Disorder Associated With Myopathy and GDD
Pedigree of the large family described in this report. Circles are for female patients and squares formale patients. Dark red indicates the presence ofMD, and
green indicates findings consistent with GDD. Roman numerals are for generations in the kindred, and numerical numbers are for family members in each
generation. (+) indicates patients who have been analyzed for the ANO5 variant. ANO5 = anoctamin 5; GDD = gnathodiaphyseal dysplasia; MD = muscle
disease.
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the ANO5 variant is the cause of muscle disease. Our data
expand the phenotypic heterogeneity of ANO5-related dis-
order and support the presence of combined muscle and bone
phenotypes as a new AD subtype. It remains to be determined
whether this new entity is unique for this specific ANO5
variant or represents an emerging, probably underdiagnosed,
phenotype.
Patients with the AR ANO5-related muscle disease exhibit a
spectrum of clinical manifestations with variable severity and
age at onset. Two female patients in this kindred did not
report muscle symptoms, consistent with prior descriptions of
reduced penetrance and milder symptoms in female patients
with ANO5-related muscle disease.4 The possibility remains
that these 2 female patients have asymptomatic muscle
Figure 3 Bone Radiologic Findings in Patients With AD ANO5-Related Disorder
Radiological findings in the proband (III-1) (A–C)
and his mother (II-2) (D–G). Lateral view of right
tibia and fibula (A) and AP view of left femur (B)
showing diaphyseal thickening and reduced tab-
ulation of the tibia. Lateral view of the forearm (C)
showing significant deformities secondary to re-
peat fractures. Lateral (D) and AP (E) views of left
and right tibia and fibula, respectively, of patient
II-2 showing mid shaft cortical thickening and a
complicated fracture of right fibula. AP and lateral
skull views of patient II-2 showing postoperative
reconstruction of mandible after debulking of
COF (F and G) and severe osteopenia in cervical
spine (G). AD = autosomal dominant; COF =
cemento-ossifying fibromas.
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involvement. Muscle weakness is considered a typical finding
in this disease but was absent or mild in the 3 patients eval-
uated in this study. The variation in muscle strength among
patients in this study can be explained by interexaminer var-
iability, variable expressivity related to additional genetic
modifiers not detected through current genetic tests, or higher
burden of muscle disease and rhabdomyolysis that led tomore
persistent muscle weakness in patient IV-6. The age at onset
of muscle symptoms in the 3 patients was earlier than that
reported among patients with the mild form of the AR disease.
The prominent finding in our cohort was the episodic nature
of muscle symptoms, ranging from muscle cramps and
rhabdomyolysis to compartment syndrome, which affected
patients’ quality of life and their daily life activities. While
rhabdomyolysis has been occasionally reported in ANO5-
related muscle disorder,5 there have been no reports of
compartment syndrome. Furthermore, muscle cramps have
been rarely reported in the AR ANO5-related muscle disor-
der.6 The underlying physiologic mechanism of muscle
cramps is not well understood, but different hypotheses have
been proposed.7 The nonspecific myopathic findings in
muscle biopsy and normal or mild myopathic motor units on
EMG are consistent with previous reports.5
To date, 9 missense ANO5 variants have been reported in
heterozygous state,1,8 3 of which, including p.Thr513Ile, are
located in exon 15. Despite the fact that Thr513 is not evo-
lutionarily conserved, several lines of evidence support path-
ogenicity of the ANO5 variant. First, it has not been observed
in healthy control databases. Second, this variant segregates
well with the combined bone and muscle phenotypes in this
kindred and was reported in association with GDD inmultiple
individuals from a single family.9 Of interest, 1 patient in the
previously reported family had elevated CK levels, but no
additional details about muscle disease were provided.9 Third,
recent published functional studies demonstrated increased
phospholipid scrambling.10
ANO5 protein is predominantly localized intracellularly, with
smaller localization to the plasma membrane. It acts as a
calcium‐activated chloride channel or phospholipid scram-
blase.11 Lack of ANO5 impairs the repair ability of injured
myoblasts through dysregulated calcium homeostasis.12
ANO5 mutant protein carrying the p.Thr513Ile variant me-
diates scramblase activity independent of elevated cytosolic
calcium and carries large outward currents even at extremely
low intracellular calcium, suggesting a gain-of-function
mechanism.8 On the other hand, variants associated with
the muscle phenotype were associated with a loss‐of‐function
phenotype in the same in vitro model.10 However, this phe-
notypic and molecular dichotomy is not supported by our
data, and therefore, alternative mechanistic models should be
investigated. Furthermore, mouse models yielded conflicting
results, including sarcolemma repair abnormalities and de-
fective myoblast regeneration and fusion,13 lack of muscle
phenotype,14 GDD phenotype15 in Ano5-knockout mice, as
well as absence of skeletal phenotype in a knock-in model of a
GDD-related mutation.16 These data indicate that additional
studies are needed to delineate the ANO5 function and the
pathomechanisms of the 2 associated phenotypes.
Limitations of this study include neurologic evaluation per-
formed by different medical professionals, lack of full clinical
assessment for all family members in this kindred, and tar-
geted genetic testing for the familial ANO5 variant or neu-
romuscular panels except for the proband who had ES.
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